Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.

HIV-1/HAART-associated lipodystrophy syndrome (HALS) has been associated with exposure to stavudine (d4T) through mitochondrial dysfunction. We performed a 48-week study to assess the effects of switching from d4T to raltegravir (RAL) on metabolic and fat molecular parameters of patients with HALS....

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
Główni autorzy:	Pere Domingo, María del Mar Gutierrez, José Miguel Gallego-Escuredo, Ferran Torres, Gracia María Mateo, Joan Villarroya, Ignacio de los Santos, Joan Carles Domingo, Francesc Villarroya, Luis Del Rio, Vicente Estrada, Marta Giralt
Format:	Artigo
Język:	Inglês
Wydane:	Public Library of Science (PLoS) 2014-01-01
Seria:	PLoS ONE
Dostęp online:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0089088&type=printable
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.

Podobne zapisy